{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T11:43:21Z","timestamp":1784979801314,"version":"3.55.0"},"reference-count":24,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T00:00:00Z","timestamp":1671580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Kyowa Kirin B.V.","award":["8224-41473"],"award-info":[{"award-number":["8224-41473"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Erythrodermic cutaneous T-cell lymphoma (E-CTCL) is associated with a poor prognosis and severe symptoms. Objective: To establish insights into the quality of life (QoL), expectations, and treatment satisfaction of E-CTCL patients receiving mogamulizumab. Methods: Outcomes of this prospective cohort study conducted between September 2020 and August 2021 at the Leiden University Medical Center included the dermatology-specific QoL (Skindex-29), health-related QoL (RAND-12), degree of itch, pain, and fatigue (Visual Analogue Scale), patient\u2019s expectations, and treatment satisfaction (Client Satisfaction Questionnaire-8 (CSQ-8)), measured at baseline and after six months. Results: 13 patients with E-CTCL were included. Most patients anticipated a positive treatment effect on symptoms. Five patients (46%) improved one or more clinical categories regarding the symptoms domain, six (55%) regarding emotions, four (36%) regarding functioning, and four (36%) regarding the overall Skindex-29 score compared to baseline. The Mental Component Score clinically improved from 31 (IQR 29\u201351) at baseline to 38 (IQR 25\u201351). The median VAS itch improved significantly from baseline (8 (IQR 7\u201310) vs. 3 (IQR 1\u20138), p = 0.024). Most patients (n = 7) were \u201cvery satisfied\u201d with their treatment. Limitations: There was a limited number of patients due to the rarity of the disease. Conclusion: In general, mogamulizumab has a favorable effect on biochemical- and dermatology-specific QoL and physical functioning in some patients, with high treatment satisfaction. Itch especially improved over time in most patients. The treatment satisfaction was generally high. Mogamulizumab seems to be an effective treatment that improves the QoL in patients with E-CTCL.<\/jats:p>","DOI":"10.3390\/cancers15010032","type":"journal-article","created":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T06:11:24Z","timestamp":1671603084000},"page":"32","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Quality of Life in Cutaneous T-cell Lymphoma Patients Receiving Mogamulizumab: Important Factors to Consider"],"prefix":"10.3390","volume":"15","author":[{"given":"Rosanne","family":"Ottevanger","sequence":"first","affiliation":[{"name":"Department of Dermatology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"van Beugen","sequence":"additional","affiliation":[{"name":"Health, Medical and Neuropsychology Unit, Institute of Psychology, Leiden University, 2333 AK Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea W. M.","family":"Evers","sequence":"additional","affiliation":[{"name":"Health, Medical and Neuropsychology Unit, Institute of Psychology, Leiden University, 2333 AK Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4561-7616","authenticated-orcid":false,"given":"Rein","family":"Willemze","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5872-4613","authenticated-orcid":false,"given":"Maarten H.","family":"Vermeer","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen D.","family":"Quint","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"ref_2","first-page":"1112","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas (vol 133, pg 1703, 2019)","volume":"134","author":"Willemze","year":"2019","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/bjd.20048","article-title":"Incidence of Mycosis fungoides and Sezary syndrome in The Netherlands between 2000 and 2020","volume":"185","author":"Ottevanger","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_4","first-page":"665","article-title":"Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma","volume":"164","author":"Booken","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1111\/jdv.17570","article-title":"Quality of life in patients with Mycosis Fungoides and S\u00e9zary Syndrome: A systematic review of the literature","volume":"35","author":"Ottevanger","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jdin.2022.07.007","article-title":"Itch in patients with cutaneous T-cell lymphoma as a quality of life indicator","volume":"9","author":"Ottevanger","year":"2022","journal-title":"JAAD Int."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.clml.2020.09.003","article-title":"Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma","volume":"21","author":"Porcu","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.1182\/bloodadvances.2020003053","article-title":"Mogamulizumab for adult T-cell leukemia-lymphoma: A multicenter prospective observational study","volume":"4","author":"Yonekura","year":"2020","journal-title":"Blood Adv."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"E581","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): An international, open-label, randomised, controlled phase 3 trial (vol 19, pg 1192, 2018)","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_10","unstructured":"Agency, E.M. (2022, December 10). Poteligeo. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/poteligeo."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/S0959-8049(21)00749-8","article-title":"Health-related quality of life effect of mogamulizumab by patient blood involvement","volume":"156","author":"Zinzani","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.neubiorev.2020.03.025","article-title":"Placebo and nocebo effects for itch and itch-related immune outcomes: A systematic review of animal and human studies","volume":"113","author":"Meeuwis","year":"2020","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00432-010-0973-x","article-title":"Charlson Comorbidity Index is an independent prognostic factor among elderly patients with diffuse large B-cell lymphoma","volume":"137","author":"Kobayashi","year":"2011","journal-title":"J. Cancer Res. Clin."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/120347540100500202","article-title":"Measurement properties of Skindex-16: A brief quality-of-life measure for patients with skin diseases","volume":"5","author":"Chren","year":"2001","journal-title":"J. Cutan Med. Surg."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3109\/07853890109002089","article-title":"The RAND-36 measure of health-related quality of life","volume":"33","author":"Hays","year":"2001","journal-title":"Ann. Med."},{"key":"ref_16","first-page":"101","article-title":"The Impact of Chronic Skin Disease on Daily Life (ISDL): A generic and dermatology-specific health instrument","volume":"158","author":"Evers","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/jid.2011.138","article-title":"Interpretation of Skindex-29 scores: Cutoffs for mild, moderate, and severe impairment of health-related quality of life","volume":"131","author":"Prinsen","year":"2011","journal-title":"J. Investig. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/1523-1747.ep12365600","article-title":"Skindex, a quality-of-life measure for patients with skin disease: Reliability, validity, and responsiveness","volume":"107","author":"Chren","year":"1996","journal-title":"J. Investig. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0149-7189(82)90074-X","article-title":"The client satisfaction questionnaire. Psychometric properties and correlations with service utilization and psychotherapy outcome","volume":"5","author":"Attkisson","year":"1982","journal-title":"Eval. Program Plann."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"370","author":"Altman","year":"2007","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1182\/blood-2014-09-600924","article-title":"Phase 1\/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma","volume":"125","author":"Duvic","year":"2015","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/YCO.0b013e328343803b","article-title":"Role of expectations in health","volume":"24","author":"Colloca","year":"2011","journal-title":"Curr. Opin. Psychiatry"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(00)04169-6","article-title":"Influence of context effects on health outcomes: A systematic review","volume":"357","author":"Harkness","year":"2001","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Zhang, T., Sun, J., Li, J., Zhao, Y., Zhang, T., Yang, R., and Ma, X. (2021). Safety and efficacy profile of mogamulizumab (Poteligeo) in the treatment of cancers: An update evidence from 14 studies. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08363-w"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/1\/32\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:45:23Z","timestamp":1760147123000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/1\/32"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,21]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["cancers15010032"],"URL":"https:\/\/doi.org\/10.3390\/cancers15010032","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742485925.793597451","asserted-by":"object"}]},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,21]]}}}